Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glimepiride monotherapy versus glimepiride + linagliptin in HNF1A-diabetes
2017-000204-15Phase 2Completed
- Sponsor
- Professor, DMSc Tina Vilsbøll
- Start
- May 2017
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glimepiride and linagliptin in maturity-onset diabetes of the young type 3 (2 arms), sponsored by Professor, DMSc Tina Vilsbøll. Primary endpoint: Mean amplitude of glycaemic excursions. Started May 2017; status: completed.
02
Drugs
glimepiridelinagliptin
03
Conditions
maturity-onset diabetes of the young type 3
Beyond the preview
Go deeper on 2017-000204-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000204-15.